Marker Therapeutics, Inc.

Monthly Archives: February 2017

Vaccine could prevent breast, ovarian, lung cancer

It's a dream many parents would welcome for their children: a vaccine that could prevent breast, ovarian and some lung cancers. It's also the dream of immunology professor Dr. Keith Knutson. "The hope is we can develop vaccines before the development of cancer much in the way that we use a polio vaccine or a flu vaccine," Dr. Knutson tells us in in his Mayo Clinic Jacksonville laboratory.
Read More

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.
Read More

T.L. Williams; TapImmune; 1904 Music Hall

Monday on First Coast Connect we spoke with former CIA operative and author T. L. Williams about his new novel and Chinese cyber hacking. We also heard from TapImmune CEO Glynn Wilson about a breast cancer study at the Mayo Clinic. WJCT’s Indie Endeavor host Ryan Benk and 1904 Music Hall co-owner Jason Hunnicut announced a new partnership at the downtown venue.
Read More

TapImmune Expands Intellectual Property On PolyStartTM Platform For Use In Next-Generation T-Cell Vaccines

TapImmune, Inc. (NASDAQ: TPIV) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application titled, “Chimeric nucleic acid molecules with non-AUG initiation sequences and uses thereof.”
Read More

TapImmune improves T-cell vaccine formulation ahead of Ph II trials

If you’re a biotech investor who has not yet heard of TapImmune, Inc. (NASDAQ: TPIV), this clinical-stage immune-oncology company is charging its way through the sector with its cutting-edge vaccine technologies that are attacking ovarian and breast cancer with a whole new vengeance.
Read More

TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials

TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.
Read More